Mall of America

PharmAbcine Receives Safety Review Committee Approval to Advance to Dose Level 2 of Clinical Trial of PMC-403 with Neovascular Age-related Macular Degeneration following Dose Level 1 Safety Data

Retrieved on: 
Thursday, November 9, 2023

Safety Review Committee evaluated dose level 1 safety data of PMC-403 and approved advancing to the higher dose treatment.

Key Points: 
  • Safety Review Committee evaluated dose level 1 safety data of PMC-403 and approved advancing to the higher dose treatment.
  • The starting dose (0.7mg) of PMC-403 showed potential in improving eyesight for neovascular age-related macular degeneration patients with suboptimal response to currently available therapies.
  • In this clinical study, a maximum of 36 patients with neovascular age-related macular degeneration with suboptimal response to currently available therapy will be evaluated for safety and maximum tolerated dose (MTD) of PMC-403.
  • The SRC reviewed the clinical data for dose level 1, and all of the SRC members agreed to advance to the dose level 2.

Nasdaq-Listed AGAPE Forges Ahead with Sustainable Energy Business

Retrieved on: 
Wednesday, November 8, 2023

("Volt Industries") in Pahang as part of the Company's strategy to develop and offer sustainable energy solutions.

Key Points: 
  • ("Volt Industries") in Pahang as part of the Company's strategy to develop and offer sustainable energy solutions.
  • ATPC, which was recently listed on Nasdaq, specializes in sustainable global 'wellness' ecosystem and the development and production of advanced technology solutions for the energy sector.
  • Dato' Sri Dr. How Kok Choong, the founder of AGAPE ATP, said: "Our recent IPO on Nasdaq was just the beginning.
  • This MoA signifies ATPC's expansion into the sustainable energy space, reflecting our ambitions on both the local and global stages.

Applied BioMath, LLC Presents Quantitative Systems Pharmacology Model of T-cell Engagers for Solid Tumors at the Society for Immunotherapy of Cancer Annual Meeting

Retrieved on: 
Monday, October 30, 2023

During the conference, Fei Hua, PhD, Vice President of Modeling and Simulation Services at Applied BioMath, will present the poster entitled, "Overcoming the dose-response prediction limitation from bench to clinic for T-cell engagers: Using Quantitative Systems Pharmacology (QSP) modeling in the development of CDR404 for solid tumors."

Key Points: 
  • During the conference, Fei Hua, PhD, Vice President of Modeling and Simulation Services at Applied BioMath, will present the poster entitled, "Overcoming the dose-response prediction limitation from bench to clinic for T-cell engagers: Using Quantitative Systems Pharmacology (QSP) modeling in the development of CDR404 for solid tumors."
  • While T-cell Engagers (TCEs) offer a potentially very potent approach to treat cancer, they also have complex relationships between binding potency, exposure, and efficacy.
  • "For therapeutics with complex mechanisms of action (MoA), QSP modeling can be integral for progressing through the R&D pipeline," said John Burke, PhD, Co-founder, President and CEO.
  • "Particularly for TCEs, we've had experience where QSP modeling has tested target feasibility, optimized molecule design, predicted therapeutic index, and guided clinical trial design."

Sweet Paris Crêperie Secures Second Minnesota Location at the Legendary Mall of America®

Retrieved on: 
Monday, October 30, 2023

MINNEAPOLIS, Oct. 30, 2023 /PRNewswire/ -- Sweet Paris Crêperie & Café, the ultra-popular restaurant brand specializing in sweet and savory crêpes, hot drinks and more, has secured its second location in Minnesota at Mall of America®, the largest shopping and entertainment complex in the United States and one of the most visited tourist attractions on the globe. In August 2022, Sweet Paris announced a multi-unit deal that marked the brand's entry into the state. The brand's first Minnesota location recently opened in Woodbury, with the Mall of America location set to open in Summer of 2024.

Key Points: 
  • The brand's first Minnesota location recently opened in Woodbury, with the Mall of America location set to open in Summer of 2024.
  • The group could not be happier with the initial response from the Woodbury community to the first ever Sweet Paris Crêperie and Café restaurant in Minnesota, and look forward to bringing our unique concept to Mall of America.
  • The Mall of America store will join the 15 additional Sweet Paris locations currently open and operating around the country.
  • "Entering a premier retail center like Mall of America marks a pivotal time in Sweet Paris' history," said Allison Chavez, co-founder of Sweet Paris.

Purple Biotech Reports Potential Biomarker Data Support CM24’s Mechanism of Action

Retrieved on: 
Friday, October 6, 2023

The poster shows that higher pre-treatment levels of tumor infiltrating lymphocytes that express CEACAM1may associated with longer survival in patients treated with CM24 and nivolumab.

Key Points: 
  • The poster shows that higher pre-treatment levels of tumor infiltrating lymphocytes that express CEACAM1may associated with longer survival in patients treated with CM24 and nivolumab.
  • “These encouraging data, demonstrating increased survival of PDAC patients whose biopsies show higher CEACAM1-positive lymphocytes, are consistent with the CM24 Mechanism of Action (MoA) in suppressing the immune evasion and suggest CEACAM1 expressing lymphocytes as a potential biomarker for CM24 therapy” said Purple Biotech VP R&D, Dr. Hadas Reuveni.
  • “NETs and CEACAM1 will continue to be monitored and investigated in our ongoing randomized Phase 2 study of CM24 in pancreatic cancer patients,” stated Purple Biotech CEO, Gil Efron.
  • “We look forward to reporting data from this study in the near term.”

AM Best Assigns Credit Ratings to TruSpire Retirement Insurance Company

Retrieved on: 
Thursday, October 5, 2023

AM Best has assigned a Financial Strength Rating of A- (Excellent) and a Long-Term Issuer Credit Rating of “a-” (Excellent) to TruSpire Retirement Insurance Company (TruSpire) (Irving, TX).

Key Points: 
  • AM Best has assigned a Financial Strength Rating of A- (Excellent) and a Long-Term Issuer Credit Rating of “a-” (Excellent) to TruSpire Retirement Insurance Company (TruSpire) (Irving, TX).
  • TruSpire is a newly formed entity under Mutual of America Life Insurance Company (MoA), which is the ultimate parent.
  • For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best's Credit Ratings .
  • For information on the proper use of Best’s Credit Ratings, Best’s Performance Assessments, Best’s Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best’s Ratings & Assessments .

Synaffix to Launch New ADC Technologies at the World ADC Conference in San Diego

Retrieved on: 
Thursday, October 12, 2023

GlycoConnect™ enables any antibody to be converted into a stable conjugated ADC in a non-genetic fashion, by modifying the native antibody glycan using Synaffix's efficient enzymes and metal-free click chemistry approach.

Key Points: 
  • GlycoConnect™ enables any antibody to be converted into a stable conjugated ADC in a non-genetic fashion, by modifying the native antibody glycan using Synaffix's efficient enzymes and metal-free click chemistry approach.
  • The extension of GlycoConnect™ with High DAR Technology enables ADCs with high drug loading (6, 8 and above), while retaining high drug substance homogeneity and therapeutic index.
  • Synaffix's proprietary toxSYN™ linker-payloads provide multiple options to maximize efficacy by matching the best mechanism of action with the tumor biology specific to the ADC target.
  • The reference compound (PNU-159,682) is metabolite of the anthracycline Nemorubicin and represents a highly potent DNA topoisomerase II inhibitor.

Synaffix to Launch New ADC Technologies at the World ADC Conference in San Diego

Retrieved on: 
Thursday, October 12, 2023

GlycoConnect™ enables any antibody to be converted into a stable conjugated ADC in a non-genetic fashion, by modifying the native antibody glycan using Synaffix's efficient enzymes and metal-free click chemistry approach.

Key Points: 
  • GlycoConnect™ enables any antibody to be converted into a stable conjugated ADC in a non-genetic fashion, by modifying the native antibody glycan using Synaffix's efficient enzymes and metal-free click chemistry approach.
  • The extension of GlycoConnect™ with High DAR Technology enables ADCs with high drug loading (6, 8 and above), while retaining high drug substance homogeneity and therapeutic index.
  • Synaffix's proprietary toxSYN™ linker-payloads provide multiple options to maximize efficacy by matching the best mechanism of action with the tumor biology specific to the ADC target.
  • The reference compound (PNU-159,682) is metabolite of the anthracycline Nemorubicin and represents a highly potent DNA topoisomerase II inhibitor.

OncoHost's PROphet® Platform to Support Henlius US-Based Phase III Trial for Patients with Extensive-Stage Small Cell Lung Cancer

Retrieved on: 
Tuesday, October 3, 2023

BINYAMINA, Israel , Oct. 3, 2023 /PRNewswire/ -- OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, today announced a collaboration with Hengenix Biotech, Inc. (Henlius USA), affiliated with Shanghai Henlius Biotech, Inc., a global biopharmaceutical company with the vision to offer high-quality, affordable, and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases, and ophthalmic diseases. Henlius USA will utilize OncoHost's PROphet® platform to identify exploratory, correlative biomarkers for patients recruited in its comprehensive Phase III clinical trial (NCT05468489). The trial is evaluating the efficacy and safety of Serplulimab plus chemotherapy (carboplatin - etoposide) in previously untreated US-based patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC).

Key Points: 
  • Henlius USA will utilize OncoHost's PROphet® platform to identify exploratory, correlative biomarkers for patients recruited in its comprehensive Phase III clinical trial ( NCT05468489 ).
  • The trial is evaluating the efficacy and safety of Serplulimab plus chemotherapy (carboplatin - etoposide) in previously untreated US-based patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC).
  • "Our shared goal is to improve cancer patients' outcomes by developing robust, scientifically sound technologies to support them and their caregivers.
  • We believe that such collaborations hold the potential to bring new hope to those affected by this challenging disease."

Mall of America® Partners with Axis Communications to Enhance Safety and Visitor Experience with Modern Surveillance and Security Upgrades

Retrieved on: 
Thursday, September 7, 2023

Mall of America® (MOA) and Axis Communications today announced new upgrades to the comprehensive surveillance and security system deployed by the retail giant and popular tourist destination.

Key Points: 
  • Mall of America® (MOA) and Axis Communications today announced new upgrades to the comprehensive surveillance and security system deployed by the retail giant and popular tourist destination.
  • These upgrades include intelligent Axis cameras intended to augment the safety personnel who help maintain a safe, carefree environment for the mall’s many visitors and staff members.
  • View the full release here: https://www.businesswire.com/news/home/20230907956263/en/
    Mall of America® upgrades surveillance and security with Axis panoramic, pan/tilt/zoom (PTZ), dome, and body worn cameras.
  • “We are proud of the role Axis has played in helping Mall of America enhance its safety, security, and overall customer experience,” said Karl Radke, Midwest Business Area Director at Axis.